Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Xeris Pharmaceuticals Inc (NQ: XERS )

2.900 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 250
Open 2.900
Bid (Size) 2.850 (100)
Ask (Size) 2.980 (1)
Prev. Close 2.900
Today's Range 2.900 - 2.900
52wk Range 1.690 - 3.640
Shares Outstanding 66,497,370
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Sapiens International Posts Downbeat Results, Joins Sky Harbour And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Xeris Biopharma Reports Third Quarter 2024 Financial Results
From Xeris Biopharma Holdings, Inc.
Via Business Wire

Performance

YTD
+28.04%
+28.04%
1 Month
-4.29%
-4.29%
3 Month
+6.62%
+6.62%
6 Month
+41.46%
+41.46%
1 Year
+59.34%
+59.34%

More News

Read More
Earnings Outlook For Xeris Biopharma Holdings
Via Benzinga
Xeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement With Beta Bionics
Via ACCESSWIRE
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris to Participate in Upcoming Investor Conferences
From Xeris Biopharma Holdings, Inc.
Via Business Wire
More Than $20M Bet On Precigen? Check Out These 3 Stocks Under $5 Insiders Are Aggressively Buying
Via Benzinga
Xeris Biopharma And 2 Other Penny Stocks Insiders Are Buying
Via Benzinga
XERS Stock Earnings: Xeris Biopharma Holdings Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Xeris Biopharma Reports Second Quarter 2024 Financial Results
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma Announces CEO Succession Plan
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing’s Syndrome Patients at ENDO 2024
From Xeris Biopharma Holdings, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris to Participate in the Jefferies Global Healthcare Conference
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Socket Mobile And 3 Other Stocks Under $3 Insiders Are Buying
Via Benzinga
XERS Stock Earnings: Xeris Biopharma Holdings Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Why Are Xeris Biopharma Shares Moving Monday?
Via Benzinga
Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.